Daxor (NASDAQ:DXR) Stock Price Down 0.9% – Time to Sell?

Shares of Daxor Corporation (NASDAQ:DXR) were down 0.9% on Thursday . The stock traded as low as $10.48 and last traded at $10.39. Approximately 314 shares changed hands during mid-day trading, a decline of 80% from the average daily volume of 1,593 shares. The stock had previously closed at $10.48.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Daxor in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

Daxor Stock Down 2.9%

The business’s 50 day moving average is $10.37 and its 200 day moving average is $10.85.

Institutional Trading of Daxor

Several hedge funds and other institutional investors have recently made changes to their positions in DXR. Aristides Capital LLC acquired a new stake in Daxor in the first quarter worth about $403,000. Crescent Grove Advisors LLC acquired a new position in shares of Daxor during the first quarter valued at about $104,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Daxor during the first quarter valued at about $245,000. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Daxor in the 4th quarter valued at approximately $184,000. Finally, Osaic Holdings Inc. purchased a new position in shares of Daxor in the 2nd quarter valued at approximately $86,000. Hedge funds and other institutional investors own 1.34% of the company’s stock.

About Daxor

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.